## Conference Agenda

**International Congress Of Therapeutic Drug Monitoring & Clinical Toxicology**

**Date:** Sunday, 19/Sept/2021

<table>
<thead>
<tr>
<th>Time</th>
<th>Location</th>
<th>Session</th>
</tr>
</thead>
<tbody>
<tr>
<td>10:30am - 8:00pm</td>
<td>Sala delle Colonne - Angelicum Congress Centre</td>
<td>Congress registration</td>
</tr>
</tbody>
</table>
| 11:00am - 3:45pm | Room A - Angelicum Congress Centre | Pre-Congress (CME): Pharmacometrics-enhanced TDM  
Session Chair: Sven van Dijkman  
Session Chair: Brenda de Winters  
11.00 am - 01.00 pm: SESSION 1: Precision Dosing  
11.00 am: Talk 1 Population approach basics. Erwin Dreesen, Maurice Ahsman  
11.30 am: Talk 2 Covariate modelling. Iris Minichmayr  
12.00 pm: Talk 3 Hands-on 1: Developing a basic PK model. All present PMX committee members  
01.00 pm: Lunch  
01.45 pm - 03.45 pm: SESSION 2: Precision dosing and Clinical Trial Design  
01.45 pm: Talk 4 Model-informed precision dosing. Sebastian Wicha, Brenda de Winter  
02.15 pm: Talk 5: Clinical trial design. Sven van Dijkman  
02.45 pm: Elective hands-on:  
- Hands-on 2: Treatment individualisation using InsightRX and TDMx. Brenda de Winter, Sebastian Wicha + committee members  
- Hands-on 3: Clinical Trial Design. Sven van Dijkman + committee members |
| 11:00am - 3:45pm | Room B - Angelicum Congress Centre | Pre-Congress (CME): TDM in pediatric patients as well as in neonates  
Session Chair: Alberto Villani  
Session Chair: Bianca Maria Goffredo  
11.00 am - 01.00 pm: SESSION 1  
11.00 am: Welcome - Franco Locatelli  
11.10 am: TDM in children supported with ECMO. Matteo Di Nardo  
11.40 am: Adverse drug reactions and pediatric intensive care. What impact? Morida Khalil Ramla  
12.10 pm: Informed use biologics in rheumatology. Fabrizio De Benedetti  
12.40 pm: Discussion/Questions  
01.00 pm: Lunch  
02.00 pm - 03.45 pm: SESSION 2  
02.00 pm: Drug monitoring in human milk from women after labor analgesia. Andrea Dotta  
02.30 pm: TDM in paediatric haematology. Pietro Merli  
03.00 pm: Neonatal pharmacology: how to improve the dosing regimens for TDM compounds based on PK modeling. Anne Smits  
03.30 pm: Discussion/Questions and closing considerations |
| 4:00pm - 4:45pm | Aula Magna - Angelicum Congress Centre | Welcome address  
Welcome address: Mario Regazzi & Franco Locatelli  
Presidential Welcome address: Yusuke Tanigawara |
| 4:45pm - 5:30pm | Aula Magna - Angelicum Congress Centre | Plenary Lecture 1: Precision Dosing: A view from industry  
Plenary Speakers: Richard W. Peck, Hoffman La Roche |
<p>| 5:30pm - 6:00pm | Aula Magna - Angelicum Congress Centre | Irving Sunshine Award |
| 6:00pm - 9:00pm | Aula Magna - Angelicum Congress Centre | Welcome cocktail |</p>
<table>
<thead>
<tr>
<th>Time</th>
<th>Event</th>
<th>Location</th>
<th>Details</th>
</tr>
</thead>
<tbody>
<tr>
<td>7:30am - 8:30am</td>
<td>Morning roundtable session: Antibiotic stability in elastomeric pumps used for outpatient parenteral antimicrobial therapy</td>
<td>Hotel The Hive</td>
<td>Chair: Dario Cattaneo</td>
</tr>
<tr>
<td>7:30am - 8:30am</td>
<td>Morning roundtable session: Alternative sampling devices to collect dried blood microsamples: state-of-the-Art</td>
<td>Hotel The Hive</td>
<td>Chair: Birgit Kock  Chair: Christophe Stove</td>
</tr>
<tr>
<td>7:30am - 8:30am</td>
<td>Morning roundtable session: TDM of taxanes</td>
<td>Hotel The Hive</td>
<td>Chair: Salvatore J. Salamone</td>
</tr>
<tr>
<td>8:00am - 7:00pm</td>
<td>Congress registration</td>
<td>Sala delle Colonne - Angelicum Congress Centre</td>
<td></td>
</tr>
<tr>
<td>8:45am - 9:00am</td>
<td>Presidential address</td>
<td>Aula Magna - Angelicum Congress Centre</td>
<td></td>
</tr>
<tr>
<td>9:00am - 9:45am</td>
<td>Plenary Lecture 2 (CME): The New Psychoactive Substances: availability, effects and new diagnostic needs. Plenary Speaker: Carlo Locatelli</td>
<td>Aula Magna - Angelicum Congress Centre</td>
<td></td>
</tr>
<tr>
<td>9:45am - 10:15am</td>
<td>Pippenger Award</td>
<td>Aula Magna - Angelicum Congress Centre</td>
<td></td>
</tr>
<tr>
<td>10:30am - 11:00am</td>
<td>Morning coffee &amp; tea, exhibition and poster viewing</td>
<td>Angelicum Congress Centre</td>
<td></td>
</tr>
</tbody>
</table>
| 11:00am - 12:30pm  | Symposium 1: New issues in Immunosuppression                           | Aula Magna - Angelicum Congress Centre | Session Chair: Stein Bergan  Session Chair: Franco Locatelli  
|                   |                                                                       |                  | 11.00 am: Talk 1: Biomarkers in solid organ transplantation. Stein Bergan  
|                   |                                                                       |                  | 11.30 am: Talk 2: TDM of immunosuppressive, beyond transplantation-the JAK inhibitors. Raman Venkataramanan  
|                   |                                                                       |                  | 12.00 pm: Talk 3: Immunosup PK and physical activity. Massimo Baraldo |
| 11:00am - 12:30pm  | Symposium 2: The “NPS (New Psychoactive Substances) phenomenon”         | Room A - Angelicum Congress Centre | Session Chair: Franco Tagliaro  
|                   |                                                                       |                  | 11.00 am: Talk 4: Pharmaco-toxicological aspects of NPS. Matteo Marti   
|                   |                                                                       |                  | 11.25 am: Talk 5: The European Early warning system on new psychoactive substances. Michael Evans-Brown  
|                   |                                                                       |                  | 11.50 am: Talk 6: NPS testing in emergency departments: screenings and quantification. Antonella Valli  
|                   |                                                                       |                  | 12.15 pm: Talk 7: Biological samples for the determination of recreational substances. Sabina Strano Rossi |
| 11:00am - 12:30pm  | Oral Session: Pharmacogenetics                                          | Room B - Angelicum Congress Centre | Session Chair: Ron Van Shaik  Session Chair: Antonio D'Avolio   |
| ID: 406            | Limited precision of CYP2D6 diplotype scores in predicting in vivo metabolizer phenotypes |                  | Prof. Espen Molden  Diakonhjemmet Hospital, Center for Psychopharmacology, Norway |
| ID: 182            | An easy, fast and inexpensive multiplex pharmacogenetics assay to simultaneously analyze clinically relevant genetic polymorphisms in CYP3A4, CYP3A5, CYP1A2, CYP2C9, CYP2C19, CYP2D6, ABCB1 and VKORC1 genes |                  |                                                      |
Dr. Camille Tron1,2,3, Régis Bouvet4, Dr. Marie-Clémente Verdier1,2,3, Dr. Christèle Dubourg4, Prof. Marie-Dominique Galibert4, Prof. Eric Bellissant1,2,3
1Pharmacology Department, Rennes University Hospital, Rennes, France; 2CIC 1414 (Clinical Investigation Center), INSEERM, Rennes, France; 3Experimental and Clinical Pharmacology Laboratory, University of Rennes, Rennes, France; 4Department of Molecular Genetics and Genomics, Rennes Hospital University, Rennes, France

ID: 412
Impact of CYP2B6 and CYP2C9 on serum concentration of sertraline in patients carrying a CYP2C19 *1/*1 genotype
Line Skute Bråten1,2, Prof. Espen Molden1,3, Dr. Marianne Kristiansen Kringen1,2
1Center for Psykofarmakologi, Diakonhjemmet Sykehus; 2Faculty of health sciences, Oslo Metropolitan University (OsloMet); 3School of Pharmacy, University of Oslo

ID: 230
Escitalopram Metabolite Profiles According to CYP2C19 and CYP2D6 Genotypes
Kristine Hole1, Pari Faraj1,2, Astrid Hermansen1, Espen Molden1,2
1Centre for Psychopharmacology, Diakonhjemmet hospital, Norway; 2Department of Pharmaceutical Biosciences, School of Pharmacy, University of Oslo, Norway

ID: 374
How strong is pharmacogenetics in psychiatry? Our experience in clinical practice
Dr. Cristina Montrasio1, Dr. Stefania Cheli1, Prof. Emilio Clementi1,2
1Unit of Clinical Pharmacology, Department of Laboratory Medicine, ASST Fatebenefratelli Sacco, Milan, Italy; 2Unit of Clinical Pharmacology ASST Fatebenefratelli Sacco, Department of Biomedical and Clinical Sciences L. Sacco, Università di Milano, 20157 Milan, Italy

ID: 310
Pharmacogenetics of anti-cancer drugs in real life settings: a monocentric experience
Dr. Cristina Montrasio1, Dr. Stefania Cheli1, Prof. Emilio Clementi1,2
1Unit of Clinical Pharmacology, Department of Laboratory Medicine, ASST Fatebenefratelli Sacco, Milan, Italy; 2Unit of Clinical Pharmacology ASST Fatebenefratelli Sacco, Department of Biomedical and Clinical Sciences L. Sacco, Università di Milano, 20157 Milan, Italy

ID: 157
Exome sequencing in oncology: a way to obtain relevant pharmacogenetic information.
Simon Verdez1,2, Juliette Albanisoon1,2, Yannis Duffourd1,2, Romain Boidot1,2, Manon Reda1,3,4, Christel Thauvin-Robinet1,2,4, Jean-David Fumet1,4, Sylvain Ladoire1, Sophie Nambo1,2, Maxime Lüu2, Patrick Callier1,2, Laurence Faivre1,2,4,7, Francois Ghiringhelli1,2,4,5,4, Picard Nicolas9
1UF Innovation en diagnostic génomique des maladies rares, Dijon, France; 2UMR1231 GAD, Inserm - Université Bourgogne-Franche Comté, Dijon, France; 3Platform of Transfer in Cancer Biology, Georges François Leclerc Cancer Center - UNICANCER, Dijon, France; 4Genomic and Immunotherapy Medical Institute, Dijon, France; 5Department of Tumour Biology and Pathology, Georges François Leclerc Cancer Center - UNICANCER, Dijon, France; 6Department of Medical Oncology, Georges François Leclerc Cancer Center - UNICANCER, Dijon, France; 7Centre de Référence maladies rares « Anomalies du Développement et syndromes malformatifs », Centre de Génétique, FHU-TRANSALD, CHU Dijon Bourgogne, Dijon, France; 8Centre d'Investigation Clinique, module Épidémiologie Clinique/Essais cliniques, CHU Dijon Bourgogne, Dijon, France; 9Inserm U1248, service de pharmacologie et toxicologie, université de Limoges, CHU de Limoges, F-87042, Limoges, France.

ID: 309
Fosfomycin therapeutic drug monitoring in real-life: development and validation of a LC-MS/MS method on plasma samples
Dr. Sara Baldelli1, Dr. Matteo Cerea2, Dr. Davide Mangioni3, Dr. Alessandra Bandera1, Dr. Dario Cattaneo1

11:00am - 12:30pm
Oral Session: TDM in real world
Session Chair: Ugo de Grazia
Session Chair: Giuliana Cangemi
AUC-based therapeutic drug monitoring of tacrolimus after renal transplant recipients is challenged by real-life data

Dr. Marte T Gustavsen1,2, Dr. Karsten Midtvedt1, Dr. Ida Robertsen2, Prof. Jean-Baptiste Woillard3,4, Dr. Jean Debord3,4, Dr. Rolf A Klaasen1, Dr. Nils Tore Vethe1, Prof. Stein Bergan1,2, Prof. Anders Åsberg1,2
1Oslo University Hospital, Norway; 2University of Oslo, Norway; 3CHU Limoges, France; 4INSERM, University of Limoges, France

Pharmacokinetic interaction between bupropion and escitalopram in patients with depression

Dr. Ragnhild Birkeland Waade1, Dr. Tore Haslemo
Center for psychopharmacology, Diakonhjemmet Hospital, Oslo, Norway

Effect of Therapeutic Plasma Exchange on the Pharmacokinetics of Itraconazole

Dr. Vincent Seah1, Dr. Sophie Stocker2, Dr. Danijela Kocic1, Dr. Stephanie Reuter3, Prof. Deborah Marriott4,5
1Department of Clinical Pharmacology & Toxicology, St Vincent's Hospital Sydney, Australia.; 2School of Pharmacy, Faculty of Medicine and Health, The University of Sydney, Australia; 3School of Pharmacy and Medical Sciences, University of South Australia, Adelaide, SA, Australia.; 4Department of Infectious Diseases and Clinical Microbiology, St Vincent's Hospital, Sydney, NSW, Australia; 5School of Medicine, University of New South Wales, Sydney, NSW, Australia.

Hydroxychloroquine blood concentrations in COVID-19 patients decline slowly after treatment cessation

Dr. Simona De Gregori1, Dr. Alessia Ballesio2, Dr. Alessandra Fusco2, Carlo Soffiantini2, Dr. Alessandro Vicentini3, Dr. Annalisa De Silvestri1, Dr. Francesco Falaschi5
1Clinical and Experimental Pharmacokinetics Unit, Fondazione IRCCS Policlinico San Matteo, Italy; 2Department of Internal Medicine, Fondazione IRCCS Policlinico San Matteo, University of Pavia, Pavia, Italy; 3Cardiac Intensive Care Unit, Arrhythmia and Electrophysiology and Laboratory of Clinical and Experimental Cardiology, Fondazione IRCCS Policlinico San Matteo, Pavia, Italy; 4Clinical Epidemiology and Biometry Unit, Fondazione IRCCS Policlinico San Matteo, Pavia, Italy; 5Internal Medicine 2, Fondazione I.R.C.C.S. Policlinico San Matteo, University of Pavia, Pavia, Italy

Therapeutic Drug Monitoring Of Quinidine In Patients With Kcnt1 Genetic Variants

Dr. Sara Cairoli1, Dr. Alessandro Ferretti2, Dr. Nicola Pietrafusa2, Dr. Alessia Vitale1, Dr. Nicola Specchio1, Dr. Carlo Dionisi Vici1, Dr. Bianca Maria Goffredo1
1Department of Pediatric Subspecialties, Division of Metabolism, Bambino Gesù Children's Hospital, IRCCS, Rome, Italy; 2Department of Neuroscience, Rare and Complex Epilepsy Unit, Bambino Gesù Children's Hospital, IRCCS, Rome, Italy

Increased accumulation of erythrocyte methotrexate polyglutamates during early phase subcutaneous versus oral methotrexate treatment of rheumatoid arthritis patients

Renske Hebing1,2, Ittai Muller1, Sohaila Mahmoud1, Marry Lin1, Dr. Sandra Heil4, Prof. Willem Lems1,2, Prof. Michael Nurmoehamed1,2, Prof. Robert de Jonge3, Dr. Gerrit Jansen2
1Reade, Rheumatology, Amsterdam, The Netherlands; 2Amsterdam UMC, location VUmc, Rheumatology, Amsterdam, Netherlands; 3Amsterdam UMC, location VUmc, Clinical Chemistry, Amsterdam, Netherlands; 4Erasmus MC, Clinical Chemistry, Rotterdam, Netherlands

11:00am - 12:30pm
Room D - Angelicum Congress Centre

Inter society Seminar (CME): Pharmacometrics Practical approaches to dose optimization
Session Chair: Antonello Di Paolo
11.00 am: Opening remarks
### ThermoFisher workshop: LC-MS/MS Platforms for Accurate, Confident Results and Regulatory-Compliant Workflows

**Presenters:**
- Speaker 1: Dr. Jonas Brand - Head of Department LCMS/HPLC/Metabolism at MVZ Labor Dr. Limbach & Kollegen GbR
- Speaker 2: Dr. Maurizio Suppo - Co-owner & Principal Consultant at Qard BV European Regulatory Services

**Presentation title:**
- Implementation of a CE/IVD Clinical LC-MS/MS Analyzer in Routine Diagnostics
- Navigating the IVDR Landscape

### Room A - Angelicum Congress Centre

**Talk 11:**
- **Title:** Point of Care urine drug screen in supporting ambulatory substance use clinic.
- **Chair:** Dr. Francesco Saverio Robustelli Della Cuna
- **Speakers:** Dr. Lucia Bernasconi, Dr. Valentina Negrini, Dr. Paola Baiardi

**Talk 12:**
- **Title:** High Resolution Mass Spectrometry drug screening in plasma and urine.
- **Chair:** Dr. Lucia Bernasconi, Dr. Valentina Negrini, Dr. Paola Baiardi
- **Speakers:** Dr. Lucia Bernasconi, Dr. Valentina Negrini, Dr. Paola Baiardi

**Talk 13:**
- **Title:** The LC-Orbitrap HR/MS in the clinical toxicology laboratory: a quality management perspective to broad-spectrum drug screening.
- **Chair:** Dr. Lucia Bernasconi, Dr. Valentina Negrini, Dr. Paola Baiardi
- **Speakers:** Dr. Lucia Bernasconi, Dr. Valentina Negrini, Dr. Paola Baiardi

**Talk 8:**
- **Title:** TDM: small molecules vs biologics.
- **Chair:** Dr. Lucia Bernasconi, Dr. Valentina Negrini, Dr. Paola Baiardi
- **Speakers:** Dr. Lucia Bernasconi, Dr. Valentina Negrini, Dr. Paola Baiardi

**Talk 9:**
- **Title:** Next generation therapeutic antibodies.
- **Chair:** Dr. Lucia Bernasconi, Dr. Valentina Negrini, Dr. Paola Baiardi
- **Speakers:** Dr. Lucia Bernasconi, Dr. Valentina Negrini, Dr. Paola Baiardi

**Talk 7:**
- **Title:** Regulatory implementation and workshop.
- **Chair:** Dr. Lucia Bernasconi, Dr. Valentina Negrini, Dr. Paola Baiardi
- **Speakers:** Dr. Lucia Bernasconi, Dr. Valentina Negrini, Dr. Paola Baiardi

**Talk 6:**
- **Title:** Implementation of a CE/IVD Clinical LC-MS/MS Analyzer in Routine Diagnostics.
- **Chair:** Dr. Lucia Bernasconi, Dr. Valentina Negrini, Dr. Paola Baiardi
- **Speakers:** Dr. Lucia Bernasconi, Dr. Valentina Negrini, Dr. Paola Baiardi

**Talk 5:**
- **Title:** Workflows for liquid chromatography/mass spectrometry platforms.
- **Chair:** Dr. Lucia Bernasconi, Dr. Valentina Negrini, Dr. Paola Baiardi
- **Speakers:** Dr. Lucia Bernasconi, Dr. Valentina Negrini, Dr. Paola Baiardi

**Talk 4:**
- **Title:** Clinical toxicology laboratory: broad-spectrum drug screening.
- **Chair:** Dr. Lucia Bernasconi, Dr. Valentina Negrini, Dr. Paola Baiardi
- **Speakers:** Dr. Lucia Bernasconi, Dr. Valentina Negrini, Dr. Paola Baiardi

**Talk 3:**
- **Title:** Spectrometry drug screening in plasma and urine.
- **Chair:** Dr. Lucia Bernasconi, Dr. Valentina Negrini, Dr. Paola Baiardi
- **Speakers:** Dr. Lucia Bernasconi, Dr. Valentina Negrini, Dr. Paola Baiardi

**Talk 2:**
- **Title:** Next generation therapeutic antibodies.
- **Chair:** Dr. Lucia Bernasconi, Dr. Valentina Negrini, Dr. Paola Baiardi
- **Speakers:** Dr. Lucia Bernasconi, Dr. Valentina Negrini, Dr. Paola Baiardi

**Talk 1:**
- **Title:** TLC: small molecules vs biologics.
- **Chair:** Dr. Lucia Bernasconi, Dr. Valentina Negrini, Dr. Paola Baiardi
- **Speakers:** Dr. Lucia Bernasconi, Dr. Valentina Negrini, Dr. Paola Baiardi
Evaluation of pre-analytical practices and intraindividual variability of uracilemia for DPD phenotyping: results of a study from the French Group of Clinical Oncological Pharmacology.

Maud Maillard1, Dr. Elodie Gautier-Veyret2, Prof. Jérôme Guittton1, Dr. Bernard Royer3, Dr. Manon Launay4, Dr. Sophie Broutin1, Dr. Céline Narjoz5, Dr. Camille Tron6, Prof. Joseph Ciccolini8, Dr. Damien Richard9, Hugo Alarcan11, Prof. Vincent Hauflroid12, Naima Tafzi13, Dr. Antonin Schmitt14, Dr. Marie-Christine Etienne-Grimaldi15, Dr. Fabienne Thomas1

1Laboratoire de Pharmacologie, Institut Claudius Regaud, IUCT-Oncoologie et Centre de Recherches en Cancérologie de Toulouse, Inserm UMR1037, Université Paul Sabatier, Toulouse, France; 2Laboratoire de Pharmacologie, Pharmaco-génétique et Toxicologie, CHU Grenoble-Alpes et Université Grenoble-Alpes, laboratoire HP2, INSERM U1042, Grenoble, France; 3Laboratoire de Pharmacologie Toxicologie, CHU de Lyon, Lyon, France; 4Laboratoire de Pharmacologie Clinique et Toxicologie, CHU de Besançon, Besançon, France; 5Laboratoire de Pharmacologie et Toxicologie, CHU de Saint-Etienne, Saint-Etienne, France; 6Département de Biologie et Pathologie Médicale, Service de Pharmacologie, Gustave Roussy, Villejuif, France; 7Assistance Publique des Hôpitaux de Paris, Hôpital européen Georges-Pompidou, Service de biochimie, Paris; 8Laboratoire de Pharmacologie, CHU de Rennes, Rennes, France; 9SMARTc Unit, CRCM Inserm U1068 et Laboratoire de Pharmacocinétique, CHU La Timone, Marseille, France; 10Laboratoire de Pharmacologie et Toxicologie, CHU de Clermont-Ferrand, Clermont-Ferrand, France; 11Service de Biochimie et Biologie Moléculaire, CHRU de Tours, Tours, France; 12Louvain centre for Toxicology and Applied Pharmacology (LTAP), Clinical and Experimental Research Institute (IREC), Université catholique de Louvain, Brussels, Belgium; 13INserm, Université de Limoges, Service de Pharmacologie et Toxicologie, CHU de Limoges, U1248 IP RRITT, Limoges, France; 14Service Pharmacie, Centre Georges-François Leclerc et INSERM U1231, Université de Bourgogne, Dijon, France; 15Laboratoire d’Oncopharmacologie, UPRC EA 7497, Centre Antoine Lacassagne, Nice, France

ID: 196

Short- and long-term effect of gastric bypass and calorie restriction on CYP3A activity in patients with severe obesity

Kine Eide Kvitr
University of Oslo, Norway

ID: 202

Influence of green tea flavonoids on the bioavailability of nintedanib: a randomized, cross-over study in patients with pulmonary fibrosis

Dr. GD Marijn Veerman1, Dr. Marlies S Wijzenbeek2, Sanne C van der Werff3, Dr. Jelle R Miedema3, Dr. Esther Oomen-de Hoop1, Dr. Sophie C van der Mark2, Dr. Prewesh P Chandoesing4, Dr. Stijn LW Koolen1,2, Prof. Ron HJ Mathijssen1

1Dept. of Medical Oncology, Erasmus MC Cancer Institute, Rotterdam, the Netherlands; 2Dept. of Pulmonology, Erasmus MC, Rotterdam, the Netherlands; 3Dept. of Hospital Pharmacy, Erasmus MC, Rotterdam, the Netherlands

ID: 159

Assessing the binding interaction of polystyrene sulfonate with amitriptyline in healthy volunteers, a cross-over design: The BIND study

Ilona Prins-Ca1, Inge Regina Francina van Berlo-van de Laar1,2, Marieke Zeeman3, Cornelis Gerard Vermeij2, Esther van ‘t Riet4, Katja Taxis5, Franciscus Gerhardus Antonius Jansman1

1Deventer Teaching Hospital, The Netherlands, Department of Clinical Pharmacy; 2University of Groningen, The Netherlands; 3Groningen Research Institute of Pharmacy (GRIP), Unit of Pharmacotherapy, - Epidemiology & Economics; 4Deventer Teaching Hospital, The Netherlands, Department of Geriatrics; 5Deventer Teaching Hospital, The Netherlands, Department of Nephrology; 6Deventer Teaching Hospital, The Netherlands, Research Department

ID: 170

Multi-Site Evaluation of Immunoassays for Antipsychotic Drug Measurement in Clinical Samples

Prof. William A Clarke3, Bruce Slayer4, Casey Hussey1, Dr. JoAnn Gardiner2, Prof. Kamisha Johnson-Davis1,4, Dr. Michael C Milone2, Dr. Salvatore J Salamone4

1Johns Hopkins University School of Medicine, United State of America; 2Perelman School of Medicine of the University of Pennsylvania, United State of America; 3University of Utah Health Sciences Center, Department of Pathology, United States of America; 4ARUP Institute for Clinical and Experimental Pathology, United State of America; 5Saladax Biomedical, Inc., United States of America
| ID: 305 | Validation of Point of Care Tests (POCT) of Antipsychotic Drugs Aripiprazole and Risperidone  
DeWayne M. Davenport, Mary Rose Hilaire, Nathan A. Siegfried, Jodi Courtney, Irina Baburina, Regina V. Gill, Megan S. Konrath, Tasafia Habiba, Barrie A. Rogers, Adrienne Drisgill, Salvatore J. Salamone  
Saladax Biomedical, Inc. United States of America |
| ID: 446 | National early warning system on New Psychoactive Substances  
Dr. Simona Pichini  
Analytical Pharmacotoxicology Unit Head, National Centre on Addiction and Doping, Istituto Superiore di Sanità |
| ID: 407 | Evaluation of a new immunoassay method for the evaluation of traditional and designer benzodiazepines in urine  
Prof. Luca Morini, Brian Rossi, Francesca Freni, Giancarlo Collo, Dr. Cristiano Stramesi, Claudia Vignali  
Department of Public Health, Experimental and Forensic Medicine, University of Pavia, Italy |
| ID: 268 | Identification of the metabolites of four new designer benzodiazepines with the help of molecular networks.  
Michiel Notelaers, Prof. Alain Gaston Verstraete  
1Department of diagnostic sciences, Ghent university, Belgium; 2Department of laboratory medicine, Ghent university hospital, Belgium |
| ID: 175 | In vitro toxicokinetics of three novel stimulants of the (2-aminopropyl)benzothiophene type including cellular uptake, metabolic fate, isozyme mapping, and monoamine oxidase inhibition  
Dr. Lea Wagmann, Fabian Frankenfeld, Dr. Simon D Brandt, Ole Jensen, Prof. Jürgen Brockmöller, Prof. Markus R Meyer  
1Saarland University, Homburg, Germany; 2Liverpool John Moores University, Liverpool, UK; 3University Medical Center Göttingen, Göttingen, Germany |
| ID: 185 | A LC-MS/MS method for the detection of two phosphatidylethanol homologues as long-term biomarkers of alcohol exposure  
Prof. Kamisha L. Johnson-Davis, Dr. Nkemakonam C. Okoye, Dr. Chad D. Moore  
1University of Utah / ARUP Laboratories, United States of America; 2ARUP Institute for Clinical and Experimental Pathology, United States of America; 3Sports Medicine and Research Testing Laboratory, United States of America |
| ID: 375 | Severe intoxications associated with analytically confirmed use of NBOMe and 2C phenethylamines  
Dr. Azzurra Schicchi, Dr. Davide Lonati, Dr. Valeria M Petrolini, Dr. Eleonora Buscaglia, Dr. Antonella Valti, Dr. Giulia Scaravaggi, Dr. Pietro Papa, Prof. Carlo Locatelli  
1Toxicology Unit, Pavia Poison Center-National Toxicology Information Centre, Clinical and Experimental Laboratory, IRCCS Pavia Hospital, Istituti Clinici Scientifici Maugeri, Pavia, Italy; 2Laboratory of Analytical Toxicology, Clinical Chemistry Service, IRCCS Policlinico San Matteo Foundation, Pavia (Italy) |
<table>
<thead>
<tr>
<th>Time</th>
<th>Event</th>
</tr>
</thead>
<tbody>
<tr>
<td>3:30pm - 4:20pm</td>
<td>Angelicium Congress Centre</td>
</tr>
<tr>
<td>Afternoon tea&amp;Coffee, exhibition and poster viewing</td>
<td></td>
</tr>
<tr>
<td>4:30pm - 6:00pm</td>
<td>Symposium 5: TDM of biologics in inflammatory bowel diseases</td>
</tr>
<tr>
<td>Aula Magna - Angelicium Congress Centre</td>
<td></td>
</tr>
<tr>
<td>Session Chair: Dario Cattaneo</td>
<td></td>
</tr>
<tr>
<td>04.30 pm: Talk 14: Role of proactive versus reactive TDM of anti-TNF drugs or standard of care in inflammatory bowel diseases. Dario Cattaneo</td>
<td></td>
</tr>
<tr>
<td>05.00 pm: Talk 15: Value of TDM of ustekinumab and vedolizumab in inflammatory bowel diseases. Gionata Fiorino</td>
<td></td>
</tr>
<tr>
<td>05.30 pm: Talk 16: How do we implement TDM to maximise treatment success? What target concentrations should we aim for? Anne Strik</td>
<td></td>
</tr>
<tr>
<td>4:30pm - 6:00pm</td>
<td>Symposium 6: Role of metabolite measurement in risk assessment of xenobiotic compounds: analytical and toxicokinetic aspects</td>
</tr>
<tr>
<td>Room A - Angelicium Congress Centre</td>
<td></td>
</tr>
<tr>
<td>Session Chair: Nicolas Venisse</td>
<td></td>
</tr>
<tr>
<td>04.30 pm: Talk 17: The complexity of human metabolism and how it can be explored through in vitro and in vivo approach. Markus R Meyer</td>
<td></td>
</tr>
<tr>
<td>05.00 pm: Talk 18: Bisphenol: weakness of deconjugation methods and its impact on biomonitoring. Roy Gerona</td>
<td></td>
</tr>
<tr>
<td>05.30 pm: Talk 19: The role of metabolite determination in risk assessment. Antoine Dupuis</td>
<td></td>
</tr>
<tr>
<td>4:30pm - 6:00pm</td>
<td>Oral Session: Immunosuppressants</td>
</tr>
<tr>
<td>Room C - Angelicium Congress Centre</td>
<td></td>
</tr>
<tr>
<td>Session Chair: Florian Lemaitre</td>
<td></td>
</tr>
<tr>
<td>Session Chair: Massimo Baraldo</td>
<td></td>
</tr>
</tbody>
</table>

**ID: 330**

**Contribution of the Bayesian estimate of the area under the curve in the optimization of calcineurin inhibitors’ therapeutic monitoring**

Dr. Habiba Fetati¹, Dr. Fatma Boudia¹, Dr. Abelghani Chaib¹, Dr. Nadjet Mekaouche¹, Dr. Asmaa Memou¹, Dr. Imene Ouden¹, Dr. Kada Djoudad², Dr. Brahim Bendifallah², Prof. Faiza Zerdoumi², Prof. Houari Toumi¹

¹Faculty of Medicine, University of Oran 1 Ahmed Ben Bella, Oran, Pharmacovigilance Department of the Hospital and university Establishment of Oran, Algeria; ²Nephrology Department of the Hospital and university Establishment HUE of Oran, Algeria

**ID: 150**

**Avoiding tacrolimus under- and overexposure with a dosing algorithm for renal transplant recipients: a single arm prospective intervention trial**

Marith I. Francke¹,²,³, Louise M. Andrews³,⁴, Hoang Lan Le⁴, Jaqueline van de Wetering¹,², Marian C. Claesen-van Groningen⁴,⁵, Teun van Gelder⁶, Ron H.N. van Schaik⁶, Bronno van der Holt⁶, Brenda C.M. de Winter⁶, Dennis A. Hesselink¹,²

¹Department of Internal Medicine, Division of Nephrology and Transplantation, Erasmus MC, University Medical Center Rotterdam, the Netherlands; ²Rotterdam Transplant Group; ³Netherlands Institute for Health Sciences; ⁴Department of Hospital Pharmacy, Erasmus MC, University Medical Center Rotterdam, Rotterdam, The Netherlands; ⁵Department of Hospital Pharmacy, Meander Medical Center, Amersfoort, The Netherlands; ⁶Department of Pathology, Erasmus MC, University Medical Center Rotterdam, Rotterdam, The Netherlands; ⁷Department of Clinical Pharmacy and Toxicology, Leiden University Medical Center, Leiden, the Netherlands; ⁸Department of Clinical Chemistry, Erasmus MC, University Medical Center, Rotterdam, the Netherlands; ⁹Department of Hematology, Erasmus MC Cancer Institute, Rotterdam, the Netherlands

**ID: 146**

**Drug transporters expression on PBMC membrane is associated with tacrolimus intracellular concentration**

Gwendal Coste, Dr. Jonathan Chemouny, Dr. Pauline Houssel-Debray, Prof. Mikael Roussel, Dr. Caroline Jezéquel, Dr. Camille Tron, Dr. Michel Rayar, Dr. Fabien Robin, Prof. Cécile Vigneau, Dr. Marie-Clémente Verdier, Prof. Eric Bellissant, Prof. Karim Boudjema, Prof. Bruno Lavollée, Dr. Florian Lemaitre

Rennes University Hospital, France
Intracellular tacrolimus monitoring: intra-patient medium-term variability in a cohort of pediatric patients

Dr. Alice Palermiti1, Dr. Amedeo De Nicolò1, Dr. Michele Pinori2, Dr. Jessica Cusato1, Dr. Alessandra Manca1, Dr. Jacopo Mula1, Dr. Miriam Antonucci1, Dr. Valeria Avataneo1, Dr. Elisa Delia De Vivo1, Dr. Alice Ianniello1, Dr. Pier Luigi Calvo2, Prof. Antonio D’Avolio1
1University of Turin, Amedeo di Savoia Hospital, Italy; 2Regina Margherita Children's Hospital, Turin, Italy

Clinically significant drug-drug interaction between tacrolimus and fluconazole in stable renal transplant recipient

Dr. Jiake He1,2,3, Chenglong Yin2, Hailang Liu2, Hua Zou2, Jingsheng Ma2, Wentao Yang2, Dr. Qigen Li2, Lin Zhong2, Prof. Xijing Chen3
1Department of Pharmacy, The Second Affiliated Hospital of Nanchang University, Nanchang, People's Republic of China; 2Department of Organ Transplantation, The Second Affiliated Hospital of Nanchang University, Nanchang, People's Republic of China; 3Clinical Pharmacokinetics Laboratory, School of Basic Medicine and Clinical Pharmacy, China Pharmaceutical University, Nanjing, People's Republic of China

Does inflammation impact tacrolimus metabolism in kidney transplant recipients?

Dr. Florian Lemaitre, Gwendal Coste, Dr. Camille Tron, Dr. Jonathan Chemouny
Rennes University Hospital, France

Utility of Mycophenolic Acid Therapeutic Drug Monitoring in pediatric hematopoietic stem cell transplantation patients in the first month after transplant, using a Limited Sampling Strategy developed for renal pediatric patients

Dr. Francesco Lo Ro1, Dr. Antonella Zucchetto2, Dr. Natalia Maximova3, Prof. Massimo Baraldo1,4
1Clinical Pharmacology and Toxicology Institute, “S. Maria della Misericordia” University Hospital Friuli Centrale, Udine, (Italy); 2Scientific Directorate, Centro di Riferimento Oncologico di Aviano (CRO), IRCCS, (Italy); 3Institute for Maternal and Child Health-IRCCS Burlo Garofolo, Trieste, Italy; 4Chair of Pharmacology, Department of Medical Area (DAME), UNIUD (Italy)

Mycophenolate dose adjustment in paediatric transplantation patients: Impact of a model-based dosing algorithm

Dr. Bianca Maria Goffredo1, Sara Cairoli1, Raffaele Simeoli1, Marco Dionisi2, Oscar della Pasqua3
1Bambino Gesù Children’s Hospital IRCCS, Italy; 2Istituto per le Applicazioni del Calcolo, National Research Council, Rome, Italy; 3UCL - LONDON'S GLOBAL UNIVERSITY

Nuclear factor of activated T cells as potential pharmacodynamic biomarker for the risk of acute and subclinical rejection in de novo liver recipients

Dr. Olga Millán1,2, Dr. Pablo Ruiz1, Virginia Fortuna1, Dr. Miguel Navasa1,3, Dr. Constantino Fondevila1, Dr. Mercè Brunet1,4
1Pharmacology and Toxicology, Biochemistry and Molecular Genetics, Biomedical Diagnostic Centre (CDB), IDIBAPS, Hospital Clinic of Barcelona, University of Barcelona, Spain; 2Biomedical Research Centre in Hepatic and Digestive Diseases (CiBERehd), Instituto de Salud Carlos III, Spain; 3Liver Transplant Unit, IDIBAPS, Hospital Clinic of Barcelona, University of Barcelona, Spain; 4Hepatopancreatoobiliary Surgery and Transplantation, General and Digestive Surgery Service, Hospital Clinic, IDIBAPS, University of Barcelona, Barcelona, Spain.

A regression model to predict augmented renal clearance in critically ill obstetric patients and effects on vancomycin treatment

Prof. Lian Tang

6:00pm - 7:30pm
Room B - Angelicum Congress Centre

Oral Session: Anti-infectives: antibiotics
Session Chair: Antonello Di Paolo
Session Chair: Bianca Maria Goffredo

ID: 300
The Affiliated Suzhou Hospital of Nanjing Medical University, China, People's Republic of

ID: 394
Therapeutic drug monitoring of vancomycin in Coagulase Negative Staphylococci (CoNS) bacteremia: a real-life experience in a tertiary care Pediatric hospital.
Dr. Carolina Saffioti1, Dr. Alessio Mesini1, Dr. Marcello Mariani1, Dr. Luca Grasselli1, Dr. Claudia Sette1, Dr. Sebastiano Barco1, Angelo Maffia1, Laura Barbagallo1, Dr. Elio Castagnola1, Dr. Giuliana Cangemi1
1IRCCS Istituto Giannina Gaslini, Italy; 2Università degli Studi di Genova, Italy

ID: 427
Optimisation of antibiotic dosing regimens in neonatal and paediatric sepsis: Impact of a model-based approach to antimicrobial stewardship
Dr. Raffaele Simeoli1, Dr. Bianca Maria Goffredo1, Dr. Salvatore D’Agate2
1Bambino Gesù Children's Hospital IRCCS, Italy; 2UCL - LONDON'S GLOBAL UNIVERSITY

ID: 312
The possible impact of CYP3A genotypes in linezolid underexposure
Dr. Sara Baldelli, Dr. Stefania Chelli, Dr. Dario Cattaneo, Dr. Cristina Montrasio
ASST Fatebenefratelli Sacco, Italy

ID: 324
Daptomycin and methadone: a possible drug – drug interaction
Dr. Simona De Gregori1, Dr. Annalisa De Silvestri1, Dr. Antonella Bartoli1, Dr. Riccardo Albertini1, Prof. Raffaele Bruno4, Dr. Elena Seminari4
1Fondazione IRCCS Policlinico San Matteo - Pavia, Italy - Clinical and Experimental Pharmacokinetics Unit; 2Fondazione IRCCS Policlinico San Matteo - Pavia, Italy - Clinical Epidemiology and Biometry Unit; 3Fondazione IRCCS Policlinico San Matteo - Pavia, Italy - Clinical Chemistry Laboratory; 4Fondazione IRCCS Policlinico San Matteo - Pavia, Italy - Infectious Diseases I, Department of Medical Sciences and Infectious Diseases

ID: 254
Comparison of dalbavancin pharmacokinetics in peripheral blood mononuclear cells (PBMCs) and plasma in a clinical real-life context.
Dr. Jacopo Mula1, Dr. Amedeo De Nicolò1, Dr. Miriam Antonucci1, Dr. Elisa De Vivo1, Dr. Jessica Cusato1, Dr. Alessandra Manca1, Dr. Alice Palermi1, Dr. Alice Iannelli1, Dr. Valeria Avataneo1, Dr. Giacomo Stroffolini2, Dr. Giuseppe Caritti3, Prof. Giovanni Di Perri3, Prof. Antonio D’Avolio1
1University of Turin, Department of Medical Sciences, Laboratory of Clinical Pharmacology and Pharmacogenetics, Amedeo di Savoia Hospital, Turin (Italy); 2University of Turin, Department of Medical Sciences, Unit of Infectious Diseases, Amedeo di Savoia Hospital, Turin (Italy)

ID: 285
Dalbavancin pharmacokinetics with single or dual infusions in patients with soft-tissue or osteoarticular infections.
Dr. Amedeo De Nicolò1, Dr. Giacomo Stroffolini2, Dr. Miriam Antonucci1, Dr. Jacopo Mula1, Dr. Jessica Cusato1, Dr. Alice Palermi1, Dr. Alessandra Manca1, Dr. Giuseppe Caritti2, Prof. Stefano Bonora2, Prof. Giovanni Di Perri2, Prof. Antonio D’Avolio1
1Laboratory of Clinical Pharmacology and Pharmacogenetics, Department of Medical Sciences, University of Turin, Italy; 2Unit of Infectious Diseases, Department of Medical Sciences, University of Turin, Italy

ID: 213
Belgian experience with a flucloxacillin absorption test to guide antibiotic treatment.
Nick Verougstraete1, Franky Buyle2, Pieter De Cock2, Jerina Boelens1, Sanne De Smet2, Diana Huis in ‘t Veld2, Alain Verstraete1
1Department of Laboratory Medicine, Ghent University Hospital, Ghent, Belgium; 2Department of Pharmacy, Ghent University Hospital, Ghent, Belgium

6:00pm - 7:30pm Cocktail reception and poster viewing
<table>
<thead>
<tr>
<th>Location</th>
<th>Event</th>
</tr>
</thead>
<tbody>
<tr>
<td>Angelicum Congress Centre</td>
<td>Dinner at Leisure</td>
</tr>
<tr>
<td>8:30pm - 11:00pm</td>
<td>Young Scientists dinner</td>
</tr>
<tr>
<td>Stadium of Domitian</td>
<td></td>
</tr>
</tbody>
</table>
### Morning roundtable session: New drug-drug interactions in organ transplant recipients
Chair: Florian Lemaitre

### Morning roundtable session: TDM of tirosyne kinase inhibitors
Chair: Dirk Moes

### Morning roundtable session: TDM of long-acting formulations of antipsychotics
Chair: Sara Baldelli

### Congress registration

### Plenary lecture 3 (CME): Precision medicine and information technology in ICUs.
Plenary Speaker: Stefano Finazzi

### Victor Armstrong Young Investigator Award

### Patsalos Prize

### Morning coffee & tea, exhibition and poster viewing

### Symposium 7: The issues in pediatric patients
Session Chair: Bianca Maria Goffredo
- 11.00 am: Talk 20: TDM of drugs used for analgesia/sedation. Bianca Maria Goffredo
- 12.00 pm: Talk 22: Antipsychotics monitoring in pediatric patients. Emilio Clementi

### Symposium 8: Microsampling devices: assay developments and applications
Session Chair: Antonio D'Avolio
- 11.00 am: Talk 23: Dried blood microsampling: new devices, automation, and toxicological and clinical implementation. Sigrid Deprez
- 11.30 pm: Talk 24: DBS and the difficulties one encounters when implementing such a strategy in practice. Marith Francke
- 12.00 pm: Talk 25: Direct mass spectrometric analysis from VAMS. Karin Kipper

### Symposium 9: Diagnosing drug-induced liver injury (DILI)
Session Chair: Yusuke Tanigawara
- 11.00 am: Talk 26: Adverse drug reactions caused by genetic variation of drug transporters. Yusuke Tanigawara
- 11.30 am: Talk 27: Predicting hypersensitivity drug reactions mitochondrial toxicity and cytokine storm. Manuela Neuman
- 12.00 pm: Talk 28: Liver injury produced by amatoxins and phallotoxins. Eberhard Wieland

### Oral Session: Pharmacometrics
Session Chair: Sebastian Wicha
Session Chair: Oscar Della Pasqua

---

**ID: 181**
Boosting Model-Informed Precision Dosing with Machine Learning: Improving predictions in atypical patients
Dr. Jasmine Hannah Hughes, Dr. Ron Keizer
InsightRX, United States of America

**ID: 355**
A Reinforcement Learning Tool for Population Modeling
Neonatal PBPK model of buprenorphine: Identification of factors driving PK variability in newborns with neonatal opioid withdrawal syndrome

Matthijs W. van Hoogdalem1,2, Dr. Trevor N. Johnson3, Dr. Brooks T. McPhail1,4, Dr. Suyog Kamatkar5,6, Dr. Alexander A. Vinks1,7,8, Dr. Tomoyuki Mizuno1,7,8
1Division of Clinical Pharmacology, Cincinnati Children’s Hospital Medical Center, Cincinnati, OH, USA; 2James L. Winkle College of Pharmacy, University of Cincinnati, Cincinnati, OH, USA; 3Certara UK Limited, Sheffield, UK; 4School of Medicine Greenville, University of South Carolina, Greenville, SC, USA; 5Perinatal Institute, Division of Neonatology, Cincinnati Children’s Hospital Medical Center, Cincinnati, OH, USA; 6Community Hospital East, Indianapolis, IN, USA; 7Department of Pediatrics, College of Medicine, University of Cincinnati, Cincinnati, OH, USA; 8Center for Addiction Research, College of Medicine, University of Cincinnati, Cincinnati, OH, USA; 9IC42 Clinical Research and Development, University of Colorado, Aurora, CO, USA

Population pharmacokinetics of oxycodone and active metabolites in patients with cancer-related pain

Bram Agema1,2, Astrid Oosten1, Sebastiaan Sassen2, Wim Rietdijk2, Carin Van der Rijt1, Birgit Koch2, Ron Mathijssen1, Stijn Koolen1,2
1Dept. of Medical Oncology, Erasmus MC Cancer Institute, Erasmus University Medical Center, Rotterdam, The Netherlands; 2Clinical Pharmacy, Erasmus University Medical Center, Rotterdam, The Netherlands

Neural network modelling does not yield better results than Xgboost for the prediction of MPA exposure in large kidney transplantation datasets

Dr. Jean-Baptiste Woillard1,2, Dr. Marc Labriffe1,2, Dr. Jean Debord1,2, Prof. Pierre Marquet1,2
1INSERM U1248, University of Limoges, France; 2Department of Pharmacology and Toxicology, Limoges University Hospital, France


Dr. Félicien Le Louedec1,2, Dr. Florent Puisset2,3, Dr. Fabienne Thomas1,2,3, Dr. Mélanie White-Koning23, Prof. Etienne Chatelut1,2
1Pharmacology Department, Institut Universitaire du Cancer de Toulouse - Oncopole, Toulouse, France; 2Team 14 (Dose Individualization of Anticancer Drugs), Centre de Recherches en Cancérologie de Toulouse, Inserm UMR1037, Toulouse, France; 3Faculté de Pharmacie, Université Paul Sabatier, Toulouse, France; 4Pharmacy Department, Institut Universitaire du Cancer de Toulouse - Oncopole, Toulouse, France

Population pharmacokinetic and target attainment of fosfomycin disodium in healthy male volunteers

Angela Elma Edwina1, Birgit Koch1, Valentin al Jalali2, Peter Matzneller2, Markus Zeilinger2, Sebastiaan Sassen1
1Department of Hospital Pharmacy, Erasmus University Medical Center, Rotterdam; 2Department of Clinical Pharmacology, Medical University of Vienna, Vienna, Austria

11:00am - 12:30pm Seminario Intersocietario (ECM): Il paziente fragile
Session Chair: Antonello Di Paolo
11.00 am: Saluti ed apertura dei lavori
11.05 am: Terapie croniche e comorbidità nel paziente anziano. Fabio Monzani
11.25 am: Terapie concomitanti nel paziente trapiantato. Paolo De Simone
11.45 am: TDM nel paziente fragile. Mariela Marinova
12.05 pm: Discussione
12.25 pm: Considerazioni conclusive

Room D - Angelicum Congress Centre

12:30pm - 1:00pm ThermoFisher workshop: TDM by LC-MS/MS in pediatrics: from bench to bedside
<table>
<thead>
<tr>
<th>Time</th>
<th>Event</th>
<th>Location</th>
<th>Chair/Speaker</th>
</tr>
</thead>
<tbody>
<tr>
<td>12:30pm</td>
<td>Promise Proteomics workshop: Pharmacometrics of biologics in oncology: any room for therapeutic drug monitoring?</td>
<td>Room A - Angelicum Congress Centre</td>
<td>Dr Joseph Ciccolini - Professor of Pharmacokinetics, Clinical Pharmacologist (PU-PH)</td>
</tr>
<tr>
<td>12:30pm</td>
<td>Business meeting - Clinical Toxicology/Drugs of Misuse Committee</td>
<td>Room D - Angelicum Congress Centre</td>
<td>Manuela Neuman, Eric Franssen</td>
</tr>
<tr>
<td>12:30pm</td>
<td>Business meeting - Pharmacometrics Committee</td>
<td>Room B - Angelicum Congress Centre</td>
<td>Brenda De Winter, Jean-baptiste Woillard</td>
</tr>
<tr>
<td>12:30pm</td>
<td>Business meeting - Young Scientists Committee</td>
<td>Room C - Angelicum Congress Centre</td>
<td>Laura Elens, Brenda DeWinter</td>
</tr>
<tr>
<td>12:30pm</td>
<td>Lunch with Exhibitors</td>
<td>Angelicum Congress Centre</td>
<td></td>
</tr>
<tr>
<td>1:00pm - 1:30pm</td>
<td>ThermoFisher workshop: New workflows for the detection of TDM with LC HRMS Orbitrap</td>
<td>Aula Magna - Angelicum Congress Centre</td>
<td>Edward Goucher - Thermo Fisher Scientific</td>
</tr>
<tr>
<td>2:00pm - 3:30pm</td>
<td>Symposium 10: Therapeutic drug monitoring of biologics in immune-mediated inflammatory diseases other than IBD</td>
<td>Aula Magna - Angelicum Congress Centre</td>
<td>Floris Loeff, Teresa Tsakok, Gertjan Wolbink</td>
</tr>
<tr>
<td>2:00pm - 3:30pm</td>
<td>Symposium 11: Laboratory monitoring of COVID-19 patients</td>
<td>Room A - Angelicum Congress Centre</td>
<td>Birgit Koch</td>
</tr>
<tr>
<td>2:00pm - 3:30pm</td>
<td>Oral Session: Anti-infectives: antiviral drugs</td>
<td>Room B - Angelicum Congress Centre</td>
<td>Antonio D'Avolio, Nunzia Decembrino</td>
</tr>
</tbody>
</table>

**ID: 253**

**Intracellular evaluation of the pharmacokinetic interaction between rifampin and darunavir/ritonavir with dolutegravir**

Dr. Elisa Delia De Vivo, Prof. Andrea Calcagno, Dr. Amedeo De Nicolò, Dr. Ilaria Motta, Prof. Antonio D’Avolio, Prof. Giovanni Di Perri, Prof. Lubbe Wiesner, Dr. Ismaeil Ebrahim, Prof. Gary Maatens, Prof. Catherine Orwell, Prof. Helen McIlerron

1 University of Turin, Department of Medical Sciences, Laboratory of Clinical Pharmacology and Pharmacogenetics, Amedeo di Savoia Hospital, Turin (Italy); 2 Unit of Infectious Diseases, Department of Medical Sciences, University of Turin, Italy; 3 Division of Clinical Pharmacology, Department of Medicine, University of Cape Town, South Africa; 4 Desmond Tutu HIV Centre, Institute of Infectious Diseases and Molecular Medicine (IDM) and Department of Medicine, University of Cape Town, South Africa

**ID: 176**

**Antiretroviral drug plasma exposure according to seasonality: a TDM register of 10 years.**

Dr. Jessica Cusato, Prof. Andrea Calcagno, Dr. Jacopo Mula, Dr. Valeria Avataneo, Dr. Miriam Antonucci, Dr. Alice Palermi, Dr. Amedeo De Nicolò, Dr. Elisa Delia De Vivo, Dr. Alice Ianniello, Dr. Alessandra Manca, Prof. Antonio D'Avolio

University of Turin
ID: 217
Therapeutic drug monitoring and virological response in a cohort of HIV patients switching to dolutegravir/rilpivirine dual maintenance therapy (ANRS-BIRIDER Study)

Dr. Florian Lemaitre1, Dr. Jennifer Lagoutte-Rennois2, Dr. Marie-Claude Gagnieu3, Dr. Nicolas Venisse4, Dr. Matthieu Grégoire5, Dr. Stéphane Bouchet6, Dr. Rodolphe Garraffo7, Dr. Minh Lê8, Dr. Patrice Muret9, Dr. Emmanuelle Comets10, Dr. Caroline Solas10, Dr. Gilles Peytavin11, Anrs; Birider study group12, Anrs; AC-43. Pharmacology subgroup13

1 Univ Rennes, CHU Rennes, Inserm, EHESP, Inset (Institut de recherche en santé, environnement et travail)-UMR S 1085, Rennes, France; 2 Clinical Pharmacology Department - Minjoz University Hospital - Besancon – France; 3 Hospices Civils de Lyon - Groupement Hospitalier Sud - Service de Biochimie et Biologie Moléculaire - UM Pharmacologie-Toxicologie - 69495 Pierre-Benite; 4 CHU Poitiers, Laboratoire de Toxicologie et Pharmacocinétique, CIC Inserm 1402, Poitiers, France; 5 Clinical Pharmacology Department, Nantes University Hospital, Nantes, France; 6 Laboratoire de Pharmacologie et Toxicologie, Service de Pharmacologie Médicale, CHU Pellegrin, INSERM U1219, Bordeaux, France; 7 Pharmacologie Médicale, Faculté de Médecine et CHU de Nice, Hôpital Pasteur, Nice; 8 AP-HP, Bichat Claude Bernard Hospital, Pharmacology-Toxicology Department, 75018 Paris, France; 9 INSERM, UMRs-1144, Université de Paris, 75006 Paris, France; 10 INSERM, CIC 1414, 35700 Rennes, France; 11 Univ Rennes, INSERM, IAME, F-75006 Paris, France; 12 AP-HP, Hôpital La Timone, Laboratoire de Pharmacocinétique et Toxicologie, Unité des Virus Émergents (UVE: Aix-Marseille Univ-IRD 190-Inserm 1207), Marseille, France; 13 AP-HP, Bichat Claude Bernard Hospital, Pharmacology-Toxicology Department, 75018 Paris, France, Université de Paris, INSERM, IAME, F-75006 Paris, France; 14 ANRS-Maladies Infectieuses Emergentes

ID: 247
Towards an update of the interest of fluconazole therapeutic drug monitoring (TDM) in intensive care unit (ICU) pediatric patients

Jean Michel Monatte1, Marion Dequin2, Marceau Tanguy3, Prof. Fabrice Michel3, Dr. Renaud Vialet3, Dr. Romain Guilhaumou4, Prof. Caroline Solas5

1 APHM, Hôpital La Timone, Laboratoire de Pharmacocinétique et Toxicologie, Marseille, France; 2 Assistance-Publique, Hôpitaux de Marseille, Réanimation Néonatale, Marseille, France; 3 Assistance-Publique, Hôpitaux de Marseille, Anesthésie réanimation pédiatrique, Marseille, France; 4 APHM, Service de Pharmacologie Clinique et Pharmacovigilance, Institut de neurosciences des systèmes, Inserm UMR 1106, Université d’Aix-Marseille, France; 5 APHM, Hôpital La Timone, Laboratoire de Pharmacocinétique et Toxicologie Unité des Virus Émergents (UVE: Aix-Marseille Univ-IRD 190-Inserm 1207), Marseille, France

ID: 208
Evaluation of interactions between antiretroviral drugs and food using chemometric methods

Agnieszka Wiesner, Prof. Pawel Zagrodzki, Marek Jamrozik, Dr. Monika Marcinkowska, Prof. Pawel Paśko
Jagiellonian University Medical College, Faculty of Pharmacy, Poland

ID: 275
Bioequivalence study of two Favipiravir formulations performed during COVID-19 pandemic

Katerina Kovalyova, Gregory Tsapko, Sergey Mashchenko, Vera Volkova, Prof. Igor Kuznetsov
Pharmbiotest LLC, Ukraine

ID: 251
Pharmacokinetics of zanamivir in critically ill patients undergoing CVVH

Andre Wieringa1, Dr. Jasper Haringman2, Dr. Peter ter Horst1, Dr. Gert Jan Wagenvoort2, Dr. Birgit Koch1
1 Isala Clinics, dept. of Clinical Pharmacy, The Netherlands; 2 Isala Clinics, Laboratory of Clinical Microbiology and Infectious Diseases, The Netherlands; 3 Isala Clinics, dept. of Intensive Care, The Netherlands; 4 Erasmus MC, dept. of Clinical Pharmacy and Pharmacology, The Netherlands
**An innovative and efficient tool for clinical toxicology: a 60 patients retrospective study on drug annotation combining a Molecular Networking Approach with MetWork web application**

Romain Magny¹,², Yann Beauxis¹, Dr. Gregory Genta-Jouve¹,³, Dr. Emmanuel Bourgogne⁴,⁵

¹Université de Paris, faculté de Pharmacie, UMR 8038, Paris, France; ²Sorbonne Université UM80, INSERM UMR 968, CNRS UMR 7210, Institut de la Vision, IHU ForeSight, Paris, France; ³USR LEEISA, Guyane, France; ⁴Université de Paris, faculté de Pharmacie, laboratoire de toxicologie, Paris, France; ⁵APHP, Hopital St Antoine, France

**ID: 224**

**Analysis of Synthetic Cannabinoids Paraphernalia in two Patients admitted for drug Rehabilitation in UAE**

Dr. Abuelgasim Elrasheed Alhassan¹, Dr. Hamad Al Ghaferi², Dr. Muez Siddig³, Dr. Amir Haju⁴

¹National Rehabilitation Center, United Arab Emirates; ²National Rehabilitation Center, United Arab Emirates; ³National Rehabilitation Center, United Arab Emirates; ⁴National Rehabilitation Center, United Arab Emirates

**ID: 166**

**Probe Electrospray Ionization Mass Spectrometry (PESI) : an application for testing driving under the influence of drugs (DUID) in saliva**

Dr. Pauline Griffeuille, Dr. Elies Zarrouk, Dr. Souleiman El Balkhi, Prof. Franck Saint-Marcoux

Limoges University Hospital, France

**ID: 423**

**A case of severe adverse effects after paliperidone long-acting injection**

Dr. Giulia Scaravaggi¹, Dr. Chiara Marchetti², Dr. Azzurra Schicchi¹, Dr. Davide Lonati¹, Dr. Elisa Roda¹, Dr. Teresa Coccini¹, Dr. Valeria M Petrolini¹, Prof. Carlo Locatelli¹

¹Toxicology Unit, Pavia Poison Center - National Toxicology Information Centre, Clinical and Experimental Laboratory, IRCCS Pavia Hospital, ICS Maugeri SpA-SB, Pavia, Italy; ²Intensive Care Unit, Santa Chiara Hospital, Trento, Italy

**ID: 145**

**Confirmation of Methylphenidate and Ritalinic Acid in Urine Using Liquid Chromatography Tandem Mass Spectrometry (LC-MS/MS)**

Prof. Loralie J Langman, Darlington Danso, Dr. Paul J Jannetto

Department of Laboratory Medicine and Pathology, Mayo Clinic, Rochester, MN, USA

**ID: 401**

**Analytical identification of poisoning by the new synthetic opioid 2-methyl–AP-237**

Dr. Azzurra Schicchi¹, Dr. Antonella Valli¹, Dr. Pietro Papa², Dr. Maria Teresa Novelleti², Dr. Teresa Coccini¹, Dr. Elisa Roda¹, Dr. Davide Lonati¹, Dr. Valeria M Petrolini¹, Prof. Carlo Locatelli¹

¹Toxicology Unit, Pavia Poison Centre-National Toxicology Information Centre, Clinical and Experimental Laboratory, IRCCS Pavia Hospital, ICS Maugeri SpA-SB, Pavia, Italy; ²Laboratory of Analytical Toxicology, Clinical Chemistry Service, IRCCS Policlinico San Matteo Foundation, Pavia, Italy; ³Intensive Care Unit, Cardinal Massaia Hospital, Asti, Italy

**ID: 376**

**Haloperidol serum level after accidental intravenous administration of the decanoate salt**

Dr. Valeria M Petrolini¹, Dr. Azzurra Schicchi¹, Dr. Davide Lonati¹, Dr. Eleonora Buscaglia¹, Dr. Giulia Scaravaggi¹, Dr. Antonella Valli¹, Dr. Pietro Papa², Prof. Carlo Locatelli¹

¹IRCCS Pavia Hospital, Istituti Clinici Scientifici Maugeri, Pavia, Italy; ²Laboratory of Analytical Toxicology, Clinical Chemistry Service, IRCCS Policlinico San Matteo Foundation, Pavia, Italy

---

**3:30pm - 4:20pm**

**Angelicum Congress Centre**

**Afternoon tea&Coffee, exhibition and poster viewing**

**4:30pm - 6:00pm**
<table>
<thead>
<tr>
<th>Time</th>
<th>Session</th>
</tr>
</thead>
</table>
| 4:30 pm - 6:00 pm | Symposium 12: Optimal sampling strategies for TDM exemplified by vancomycin  
Session Chair: Oscar Delta Pasqua  
04.30 pm: Talk 35: Common PK/PD targets for TDM and model-informed precision dosing and what the trough sample does (not) tell. Sebastian Wicha  
05.00 pm: Talk 36: Optimal sampling is not just for trial design: application to individual patients. Michael Neely  
05.30 pm: Talk 37: An interactive introduction to AUC-based dosing of vancomycin. Iris Minichmayr |
| Room A - Angelicum Congress Centre  
4:30 pm - 6:00 pm | Symposium 13: New frontiers of clinical toxicology labs  
Session Chair: Eberhard Wieland  
04.30 pm: Talk 38: Methadone, oxycodone and buprenorphine: are polymorphisms and metabolic evaluation of clinical relevance? Donata Favretto  
05.00 pm: Talk 39: Amanitins testing in mushrooms poisoning. Elisa Roda  
05.30 pm: Talk 40: Nano-drug delivery; dream or reality. Fabio Corsi |
| Room B - Angelicum Congress Centre  
4:30 pm - 6:00 pm | Symposium 14: Clinical implementation of Pharmacogenomics  
Session Chair: Jesse J Swen  
04.30 pm: Talk 41: Development of pharmacogenetics guidelines: from reactive to pre-emptive. Jesse J Swen  
05.00 pm: Talk 42: Implementation of pharmacogenetics in the oncological clinical practice: the experience of an Italian IRCCS- Cancer Research Center. Erika Cucchin  
05.30 pm: Talk 43: Integrating Drug-Drug-Gene interactions: a Physiologically Based Pharmacokinetic approach. Thorsten Lehr |
| Room C - Angelicum Congress Centre  
4:30 pm - 6:00 pm | Oral Session: TDM in oncology  
Session Chair: Antonello Di Paolo  
Session Chair: Romano Danesi  
ID: 271  
Dr. Salvatore J Salamone¹, Dr. Yungpeng Yang², Dr. Yuniang Ma³, Dr. Yuehao Lin², Dr. Weiting Liang⁴, Dr. Hungyun Zhao⁵, Dr. Li Zhang⁶  
¹Saladax Biomedical, Inc., United States of America; ²Sun Yat-Sen University Cancer Center, Guangzhou, China |
| Room C - Angelicum Congress Centre  
4:30 pm - 6:00 pm |  
ID: 225  
Therapeutic drug monitoring based dosing of oral targeted anticancer therapies: a prospective multicenter study  
Ruben Alexander Georg van Eerden¹, Dr. Stefanie L. Groenland², Kim Westerdijk³, Marinda Meertens⁴, Dr. Stijn L.W. Koolen⁵, Dr. Dirk Jan A.R. Moe⁶, Niels de Vries⁷, Dr. Hilde Rosing⁸, Dr. Hans-Martin Otten⁹, Dr. Annelie J.E. Vulin⁴, Dr. Ingrid M.E. Desar⁸, Dr. Alexander L.T. Imholz⁹, Prof. Hans Gelderblom⁴, Dr. Nielka P. van Erp¹⁰, Prof. Jos H. Beijnen¹¹, Prof. Alwin D.R. Huitema¹², Prof. Ron H.J. Mathijssen¹, Dr. Neeltje Steeghs¹³  
¹Department of Medical Oncology, Erasmus MC Cancer Institute, Rotterdam, The Netherlands; ²Department of Clinical Pharmacology, Division of Medical Oncology, The Netherlands Cancer Institute, Amsterdam, The Netherlands; ³Department of Medical Oncology, Radboud University Medical Center, Nijmegen, The Netherlands; ⁴Department of Pharmacy, Erasmus Medical Center, Rotterdam, The Netherlands; ⁵Department of Clinical Pharmacy & Toxicology, Leiden University Medical Center, Leiden, The Netherlands; ⁶Department of Pharmacy & Pharmacology, The Netherlands Cancer Institute, Amsterdam, The Netherlands; ⁷Department of Medical Oncology, Meander Medical Center, Amersfoort, The Netherlands; ⁸Department of Medical Oncology, Reinier de Graaf Hospital, Delft, The Netherlands; ⁹Department of Medical Oncology, Delft Center Hospital, Delft, The Netherlands; ¹⁰Department of Medical Oncology, Leiden University Medical Center, Leiden, The Netherlands; ¹¹Department of Pharmacology, Radboud University Medical Center, Nijmegen, The Netherlands; ¹²Department of Pharmaceutical Sciences, Utrecht University, Utrecht, The Netherlands; ¹³Department of Clinical Pharmacy, University Medical Center Utrecht, Utrecht University, Utrecht, The Netherlands |
| Room C - Angelicum Congress Centre  
4:30 pm - 6:00 pm |  
ID: 242  
Therapeutic drug monitoring of tamoxifen to improve adjuvant treatment of hormone sensitive breast cancer  
Louwrens Braat¹, Agnes Jager¹, Esther Oomen-de Hoop², Justin Westenberg¹, Koen Lommen³, Peter de Bruijn⁴, Mirjana Vastbinder⁴, Quirine van Rossum-Schornagel⁵, Martine Thijss-Visser⁶, Robbert van Alphen⁷, Liesbeth Struijk⁸, Hanneke Zuitenhorst⁹, Ron Mathijssen¹, Stijn Koolen¹  
¹Erasmus Medical Center, Rotterdam, The Netherlands; ²Jisselland Hospital, Capelle aan den IJssel, The Netherlands; ³Franciscus Gasthuis & Vlietland, Schiedam, The Netherlands; ⁴Ikazia Hospital, Rotterdam, The Netherlands; ⁵Elisabeth Tweesteden Hospital, Tilburg, The Netherlands |
ID: 241
Determination of blood-plasma ratios of tyrosine kinase inhibitors to allow implementation of (dried) blood microsampling methods.
Nick Verougstraete\textsuperscript{1,2}, Veronique Stove\textsuperscript{2}, Alain Verstraete\textsuperscript{2}, Christophe Stove\textsuperscript{3}
\textsuperscript{1}Laboratory of Toxicology, Department of Bioanalysis, Faculty of Pharmaceutical Sciences, Ghent University, Ghent, Belgium; \textsuperscript{2}Department of Laboratory Medicine, Ghent University Hospital, Ghent, Belgium

ID: 281
A Population Pharmacokinetic Approach to Evaluate the Performance of 5-Fluorouracil Therapeutic Drug Monitoring Strategies
Dr. Hayley B Schultz, Dr. Stephanie E Reuter
Quality Use of Medicines and Pharmacy Research Centre, University of South Australia, Australia

ID: 358
A combination of pre-screening for DPD deficiency by geno/phenotypinh and PK-guided dosing of 5-FU to prevent severe toxicity in GI-cancer patients (CombiGapp): interim results
Pawida Veluwenkamp-Worawutputtapong\textsuperscript{1}, Daphne Den Besten-Bertholee\textsuperscript{1}, Dr. Helle-Brit Fiebrich-Westra\textsuperscript{2}, Dr. Richard Brohet\textsuperscript{1}, Dr. Jan Gerard Maring\textsuperscript{1}
\textsuperscript{1}Dept. of Clinical Pharmacy, Isala Hospital, The Netherlands; \textsuperscript{2}Dept. of Oncology, Isala Hospital, The Netherlands

ID: 339
Measurement of UH2/U ratio as prognostic screening of Dihydropyrimidine Dehydrogenase activity in 5-Fluorouracil therapy management
Dr. Bruno Charlier\textsuperscript{1,2}, Dr. Albino Coglianese\textsuperscript{1}, Dr. Emanuela De Bellis\textsuperscript{1}, Dr. Federica De Rosa\textsuperscript{1,2}, Dr. Francesca Mensitieri\textsuperscript{1}, Dr. Valentina Manzo\textsuperscript{1}, Dr. Berenice Stefanelli\textsuperscript{2}, Prof. Valeria Conti\textsuperscript{1,2}, Prof. Viviana Izzo\textsuperscript{1,2}, Prof. Fabrizio Dal Piaz\textsuperscript{1,2}, Prof. Amelia Filippelli\textsuperscript{1,2}
\textsuperscript{1}Department of Medicine, Surgery and Dentistry “Scuola Medica Salernitana”, University of Salerno, Baronissi.; \textsuperscript{2}University Hospital “San Giovanni di Dio e Ruggi D’Aragona”,

ID: 255
Pilot Therapeutic Drug Monitoring (TDM) Study of Pembrolizumab and Nivolumab Trough Concentrations in Melanoma Patients
Dr. Paul J. Jannetto\textsuperscript{1}, Dr. Maria A. Willrich\textsuperscript{1}, Paula M. Ladwig\textsuperscript{1}, Lisa A. Kottschade\textsuperscript{2}, Jill M. Schimke\textsuperscript{2}, Dr. Svetomir N. Markovic\textsuperscript{2}
\textsuperscript{1}Mayo Clinic, Department of Laboratory Medicine & Pathology, Rochester, MN, United States of America; \textsuperscript{2}Mayo Clinic, Department of Oncology, Rochester, MN, United States of America

ID: 336
TDM-guided empirical treatment with beta-lactams in CAR-T patients with febrile neutropenia: proof of concept
Chun Liu\textsuperscript{1,3}, Dr. Pier Giorgio Cojutti\textsuperscript{1,3}, Dr. Milo Gatti\textsuperscript{1,3}, Carla Troisi\textsuperscript{1,3}, Prof. Federico Pea\textsuperscript{1,2,3}
\textsuperscript{1}Department of Medical and Surgical Sciences, Alma Mater Studiorum, University of Bologna - Bologna (Italy); \textsuperscript{2}Clinical Pharmacology Unit, IRCCS Policlinico Sant’Orsola - Bologna (Italy); \textsuperscript{3}This project has received funding from the European Union’s Horizon 2020 research and innovation program under the Marie Skłodowska-Curie grant agreement No 861323.
Date: Wednesday, 22/Sept/2021

7:30am - 8:30am  Morning roundtable session: Interpretation of metal concentrations in blood and urine  
Chair: Souleiman El Balkhi  
Antibiotic stability in elastomeric pumps used for outpatient parenteral antimicrobial therapy. Alternative sampling devices to collect dried blood microsamples: state-of-the-Art TDM in an immune-oncology word.

7:30am - 8:30am  Morning roundtable session: Pharmacogenetics in psychiatry: is the glass half empty or half full?  
Chair: Ron Van Shaik  
Antibiotic stability in elastomeric pumps used for outpatient parenteral antimicrobial therapy. Alternative sampling devices to collect dried blood microsamples: state-of-the-art TDM in an immune-oncology word.

7:30am - 8:30am  Morning roundtable session: The use of machine learning approaches in clinical pharmacology  
Chair: Jean-Baptiste Woillard  
Antibiotic stability in elastomeric pumps used for outpatient parenteral antimicrobial therapy. Alternative sampling devices to collect dried blood microsamples: state-of-the-art TDM in an immune-oncology word.

8:00am - 5:30pm  Congress registration  
Sala delle Colonne - Angelicum Congress Centre

8:30am - 10:00am  Symposium 15: Infection site measurement of anti-microbial agents: unnecessary, a luxury or essential?  
Session Chair: Federico Pea  
08.30 am: Talk 44: Bone and joint infections. Birgit Koch  
09.00 am: Talk 45: Lungs and pleural space. Federico Pea  
09.30 am: Talk 46: The role of microdialysis. Markus Zeitlinger

8:30am - 10:00am  Symposium 16: Herbal remedies and dietary supplements  
Session Chair: Simona Pichini  
08.30 am: Talk 47: Amanita Phalloides intoxications: clinical outcomes and efficacy of antidotes – Review of 40 years of case reports. Bart G.J. Dekkers  
08.55 am: Talk 48: Herbal remedies: toxicity and effect on therapeutic drug monitoring. Vanessa Steenkamp  
09.20 am: Talk 49: Case study of curcumin food supplements: an example of public health issue. Marco Silano  
09.45 am: Talk 50: Herbal and dietary supplements use leading to toxicities. Amitava Dasgupta

8:30am - 10:00am  Oral Session: Alternative sampling strategies  
Session Chair: Ugo de Grazia  
Session Chair: Giuliana Cangemi

ID: 274  
Alternative microsampling approaches and HRMS for the monitoring of neurodegenerative disorders  
Dr. Michele Protti1, Dr. James Rudge2, Prof. Mario Amore3, Prof. Alessandro Serretti4, Prof. Laura Mercolini5  
1Research group of Pharmaco-Toxicological Analysis (PTA Lab), Department of Pharmacy and Biotechnology (FaBiT), Alma Mater Studiorum - University of Bologna, Bologna, Italy; 2Neoteryx LLC, Torrance, CA, USA; 3Department of Neuroscience, Ophthalmology, Genetics and Infant-Maternal Science, University of Genoa, Genoa, Italy; 4Department of Biomedical and Neuromotor Science, Alma Mater Studiorum - University of Bologna, Bologna, Italy

ID: 226  
Fully Automated Dried Blood Spot-Based Therapeutic Drug Monitoring of Immunosuppressants  
Sigrid Deprez, Prof. Christophe Stove  
Laboratory of Toxicology, Department of Bioanalysis, Faculty of Pharmaceutical Sciences, Ghent University, Ottergemsesteenweg 460, 9000 Ghent, Belgium

ID: 171  
Development and validation of an analytical procedure suitable for adherence monitoring of antihypertensive drugs using volumetric absorptive microsampling of finger prick blood  
Cathy M Jacobs, Dr. Lea Wagmann, Prof. Markus R Meyer
ID: 246
Interest of micro-sampling on Mitra® system for baclofen pharmacokinetics study in rats
Dr. Marie Allard1,2, Dr. Lucie Chevillard2, Nefertari Garcia-Moro1, Dr. Minh Lê1,2, Dr. Bruno Megarbane1,2, Dr. Pascal Houze1,2, Dr. Laurence Labat1,2
1Laboratoire de Toxicologie, Hopital Lariboisière, APHP, Paris, France; 2Inserm UMR-S 1144, Université de Paris, France; 3Réanimation médicale et toxicologique, Hopital Lariboisière, APHP, Paris, France; 4Laboratoire de Biochimie métabolique et nutrition, Hopital Bichat, APHP, Paris, France

ID: 205
Near-infrared-based hematocrit prediction of dried blood spots: an in-depth evaluation
Liesl Heughebaert1, Lisa Delahaye1, Dr. Christoph Lühr2, Stijn Lambrecht3, Prof. Christophe Stove1
1Ghent University, Belgium; 2BÜCHI Labortechnik, Germany; 3Ghent University Hospital, Belgium

ID: 162
Residual blood from blood gas tests can be used for therapeutic drug monitoring of vancomycin: a method comparison
Tim JL Smeets1, Anouk Rietveld1, Ruud Huisman1, Dr. Henrik Endeman1, Dr. Birgit CP Koch1, Dr. Nicole GM Humfeld1,2
1Erasmus MC, University Medical Center Rotterdam, Department of Hospital Pharmacy, Doctor Molewaterplein 40, 3015 GD Rotterdam, the Netherlands; 2Erasmus MC, University Medical Center Rotterdam, Department of Intensive Care, Doctor Molewaterplein 40, 3015 GD Rotterdam, the Netherlands

ID: 364
TDM In Haematic Miniaturised Samples Of Patients Under Polypharmacy
Camilla Marasca1,2, Prof. Marco Menchetti2, Dr. Carmine Petio1, Dr. Roberto Muratori4, Prof. Andrea Cavalli1,2, Prof. Laura Mercolini1,2, Dr. Michela Protti1
1Department of Pharmacy and Biotechnology (FaBiT), Alma Mater Studiorum – University of Bologna, 40126 Bologna, Italy; 2Italian Institute of Technology (IIT), 16163 Genoa, Italy; 3Department of Biomedical and Neuromotor Sciences, 40123 Bologna, Italy; 4Psychiatric Diagnosis and Care Service, S. Orsola-Malpighi University Hospital, 40138 Bologna, Italy

ID: 257
Tisagenlecleucel in Children and Young Adults: Reverse Translational Research by Using Real-World Safety Data
Dr. Concetta Rafaniello, Dr. Carmen Ferrajolo, Dr. Mario Gaio, Dr. Alessia Zinzi, Prof. Cristina Scavone, Dr. Maria Giuseppa Sullo, Prof. Francesco Rossi, Prof. Liberato Berrino, Prof. Annalisa Capuano
University of Campania ”L. Vanvitelli”, Italy

ID: 424
First identification of synthetic cannabinoid 5F–MDMB-PICA in Italy
Dr. Valeria M Petrolini1, Dr. Antonella Valli2, Dr. Pietro Papa2, Dr. Azzurra Schicchi1, Dr. Elisa Roda1, Dr. Teresa Coccini1, Dr. Davide Lonati1, Prof. Carlo Locatelli1
1Toxicology Unit, Pavia Poison Center-National Toxicology Information Centre, Clinical and Experimental Laboratory, IRCCS Pavia Hospital, ICS Maugeri SpA-SB, Pavia, Italy; 2Laboratory of Analytical Toxicology, Clinical Chemistry Service, IRCCS Policlinico San Matteo Foundation, Pavia, Italy

ID: 276
Hair analysis, the ideal tool for monitoring adherence to therapy in chronic pharmacological treatments?
Prof. Cristiano Fava, Dr. Francesco Taus, Dr. Marco Ballotari, Prof. Rossella Gottardo, Prof. Pietro Minuz, Prof. Franco Tagliaro
Università di Verona, Verona, Italy
Metabolism study of different classes of New Psychoactive Substances by in silico and in vivo approach.
Dr. Sara Odoardi, Dr. Serena Mestria, Dr. Giulia Biosa, Prof. Matteo Marti, Prof. Sabina Strano Rossi
1Università Cattolica del Sacro Cuore, Rome, Italy; 2University of Ferrara, Italy

Binding interactions with sevelamer and polystyrene sulfonate in vitro
Inge Regina Francina van Berlo-van de Laar, Ilona Prins-Can, Aliesa Anne de Lange, Prof. Katja Taxis, Dr. Franciscus Gerhardus Antonius Jansman
1Deventer Teaching Hospital, The Netherlands; 2University of Groningen, The Netherlands

A Systematic Review And Meta-Analysis Of Enzyme-Linked Immunosorbent Spot (Elispot) Assay For Bk Polyomavirus Immune Response Monitoring After Kidney Transplantation
Suwasin Udomkarnjananan, Stephen J. Kerr, Marith I Francke, Yingyos Avihingsanon, Nicole M. van Besouw, Carla C. Baan, Dennis A Hesselink
1Erasmus MC, Netherlands, The; 2Chulalongkorn University, Thailand

The Well Described, but Often Overlooked Mycotoxin 3-Nitropropionic Acid (3-NPA)
Dr. Philip David Walson
1University Medical Center Goettingen, Germany; 2Department of Clinical Pharmacology
The utility of Therapeutic Drug Monitoring to identify predictive factors associated to low drug levels and immunogenicity risk during therapy with Anti-TNF Biological Agents
Dr. Raffaele Simeoli1, Dr. Emminia F. Romeo1, Dr. Valeria Ventura1, Dr. Paola De Angelis2, Dr. Fiammetta Bracci2, Dr. Daniela Knafelz1, Dr. Carlo Dionisi Vici1, Dr. Bianca Maria Goffredo1
1Department of Pediatric subspecialties, Division of Metabolism, Bambino Gesù Children's Hospital-IRCCS, Rome, Italy.; 2Department of Surgery subspecialties, Digestive Endoscopy and Surgery Unit, Bambino Gesù Children's Hospital-IRCCS, Rome, Italy.; 3Department of Pediatric subspecialties, Hepatology Gastroenterology and Nutrition Unit, Bambino Gesù Children's Hospital-IRCCS, Rome, Italy.

ID: 317
One-year experience of therapeutic drug monitoring and pharmacogenetics in anti-TNF therapy
Dr. Stefania Cetti1, Dr. Valeria Cozzi2, Dr. Cristina Montrasio1, Prof. Emilio Clementi1,2, Dr. Dario Cattaneo1
1Unit of Clinical Pharmacology, ASST Fatebenefratelli Sacco University Hospital, Milan, Italy.; 2Clinical Pharmacology Unit, Consiglio Nazionale delle Ricerche Institute of Neuroscience, Department of Biomedical and Clinical Sciences L, Sacco University Hospital, Università degli Studi di Milano, Milan, Italy.

ID: 333
Evaluation of six population pharmacokinetic models of adalimumab in patients with inflammatory bowel disease in clinical practice
Silvia Márquez-Megías1, Dr. Amelia Ramón-López1,2, Dr. Patricio Más-Serrano1,2,3, Marcos Diaz-González2, Dr. Ricardo Nalda-Molina1,2
1Miguel Hernández University of Elche, School of Pharmacy, Alicante, Spain; 2Alicante Institute of Health and Biomedical Research (ISABIAL), Alicante, Spain; 3General University Hospital of Alicante, Pharmacy Department, Clinical Pharmacokinetics Unit, Alicante, Spain.

ID: 215
The impact of anti-infliximab antibodies, infliximab, circulating IL-6 and soluble TNFα in patients with rheumatoid arthritis: a repeated measures study
Miriam Casellas-Gilbert1, Helena Colom-Codina2, Javier Juanola-Roura1, Ariadna Padullés-Zamora1,2, F Javier Narváez-García4, Jordi Bas-Minguet5, Francisco Morandeira Rego6, Núria Padullés-Zamora1,2,3
1Department of Pharmacy, Hospital Universitari de Bellvitge-HUB; 2Pharmacotherapy, Pharmacogenetics and Pharmaceutical Technology Program, Institut d'Investigació Biomèdica de Bellvitge-IDIBELL; 3School of pharmacy, Universitat de Barcelona-UB; 4Department of Rheumatology, Hospital Universitari de Bellvitge-HUB; 5Department of Immunology, Hospital Universitari de Bellvitge-HUB

ID: 184
Simultaneous quantification of infliximab and adalimumab in human plasma by liquid chromatography-tandem mass spectrometry using ready-to-use kit and comparison with two ELISA methods
Dr. Camille Tron1,2, Dr. Florian Lemaitre1,2, Dr. Pauline Bros3, Dr. Claire Goulvestre4, Dr. Benedicte Francck1,2, Dr. Sandrine Bagnois4, Dr. Romain Coriat4, Dr. Nihel Khoudour4, Dr. Dorothée Lebert4, Dr. Erminia F. Romeo2, Dr. Valeria Ventura1, Dr. Maria Megías5, Dr. Patricio Más-Serrano1,2,3, Marcos Diaz-González2, Dr. Ricardo Nalda-Molina1,2, Prof. Emilio Clementi1,2
1University of Rennes, CHU Rennes, Inserm, EHESP, Inset (Institut de recherche en santé, environnement et travail) – UMR S 1085, F-35000 Rennes, France; 2Inserm, CIC-P 1414 Clinical Investigation Center, Rennes, France; 3Promise Proteomics, 7 Parvis Louis Néel, F-38040 Grenoble, France; 4Department of Immunology, Cochin Hospital, AP-HP Centre, 75014 Paris, France; 5Department of Gastroenterology, Cochin Hospital, AP-HP Centre, Université de Paris, 75014 Paris, France; 6Department of Pharmacokinetics and Pharmacochemistry, Cochin Hospital, AP-HP Centre, 75014 Paris, France; 7UMR8038 CNRS, U1268 INSERM, Faculty of Pharmacy, Université de Paris, PRES Sorbonne Paris Cité, CARPEM, 75006 Paris, France

ID: 243
Is trough concentration the best pharmacokinetic parameter for real-world infliximab exposure evaluation?
Dr. Bénédicte Franck1, Dr. Florian Lemaitre1, Dr. Sébastien Lalanne1, Dr. Marie-Céline Verdier1, Prof. Eric Bellissant1, Prof. Guillaume Bouguen4, Dr. Camille Tron1
1Department of Pharmacology, University Hospital of Rennes, France; 2Department of Gastroenterology, University Hospital of Rennes, France.
Validation of a population pharmacokinetic model of vedolizumab: application in clinical practice.
Marcos Díaz-González1,3, Dr. Ricardo Naída-Molina2,3, Dr. Amelia Ramón-López2,3, Seira Climent1, Dr. Ana Gutierrez-Casbas1, Dr. Juan Selva1,2, Josefa Boada1, Silvia Márquez-Megías1, Mari Luz Boquera1,2, Dr. Patricio Más-Serrano1,2,3
1General University Hospital of Alicante, Pharmacy Department, Clinical Pharmacokinetics Unit, Alicante, Spain; 2Miguel Hernández University of Elche, School of Pharmacy, Elche, Spain; 3Alicante Institute for Health and Biomedical Research (ISABIAL), Alicante, Spain

Oral Session: Clinical Toxicology - 3
Session Chair: Carlo Locatelli
Session Chair: Giampiero Frison

Accidental intrathecal administration of vincristine: analytical data in a lethal case
Dr. Davide Lonati1, Dr. Azzurra Schicchi1, Dr. Valeria M Petrolini1, Dr. Sara Negri2, Dr. Elisa Roda1, Dr. Teresa Cocci1, Prof. Carlo Locatelli1
1Toxicology Unit, Pavia Poison Center-National Toxicology Information Centre, Clinical and Experimental Laboratory, IRCCS Pavia Hospital, Istituti Clinici Scientifici Maugeri, Pavia, Italy; 2Environmental Research Center, IRCCS Pavia Hospital, Istituti Clinici Scientifici Maugeri, Pavia, Italy

Identification of 3-methylmethcathinone and its metabolites with artificial intelligence and molecular networks.
Florian Stijven1, Prof. Alain Gaston Verstraete1,2
1Department of diagnostic sciences, Ghent University; 2Department of laboratory medicine, Ghent university hospital, Belgium

Albumin isofoms and Serum enhanced binding (SEB) test for early Drugs Induced Liver Injuries (DILI) detection
Dr. Mohamed Ali Rahali1,2, Roy Lakis3, François Ludovic Sauvage4, Prof. Franck Saint-Marcoux1,2, Dr. Souleiman El Balkhi1,2
1CHU Limoges, France; 2University of Limoges, UMR1248, INSERM, France

Quantitative plasma concentrations in metformin-related metabolic acidosis
Dr. Azzurra Schicchi1, Dr. Elisa Roda1, Dr. Antonella Valli2, Dr. Pietro Papa2, Dr. Teresa Cocci1, Dr. Davide Lonati1, Dr. Valeria M Petrolini1, Prof. Carlo Locatelli1
1Toxicology Unit, Pavia Poison Center-National Toxicology Information Centre, Clinical and Experimental Laboratory, IRCCS Pavia Hospital, ICS Maugeri SpA-SB, Pavia, Italy; 2Laboratory of Analytical Toxicology, Clinical Chemistry Service, IRCCS Policlinico San Matteo Foundation, Pavia, Italy

First report on in vivo toxicokinetics of Dichlorobisphenol A
Noémie Plattard1,2, Dr. Sami Haddad1, Dr. Antoine Dupuis2,3, Dr. Nicolas Venisse2,3
1Department of Environmental and Occupational Health, School of Public Health, CresP, Université de Montréal, Montreal, Quebec, Canada; 2INSERM, University Hospital of Poitiers, CHU, University of Poitiers, CIC1402, HEDEX Research Group, 86021, Poitiers Cedex, France; 3Biology-Pharmacy-Public Health Department, University Hospital of Poitiers, 2 rue de la Milétrie, 86201, Poitiers Cedex, France

Human biomonitoring: a proposal for a Global Biomonitoring Institute (GBI)
Prof. John Ibhaijemien Anetor, David W. Kinniburgh, Amy M. MacDonald
Alberta Center For Toxicology, Cumming School of Medicine, University of Calgary, Canada, Canada

Measurement of pesticide residues in bee products: a French study
ID: 189
<table>
<thead>
<tr>
<th>Time</th>
<th>Event</th>
<th>Location</th>
<th>Details</th>
</tr>
</thead>
</table>
| 12:30pm - 1:00pm | ThermoFisher workshop: Trends & perspectives of anti-epileptic drug therapies and therapeutic drug monitoring, from the clinical lab to the physician. | Aula Magna - Angelicum Congress Centre | Dr. Elies Zarrouk, Arnaud Gardère, Dr. Souleiman El Balkhi, Prof. Franck Saint-Marcoux, Limoges University Hospital, France.  
Moderator: Dario Cattaneo - Professor at L. Sacco University Hospital  
- Speaker 1: Dr Karin Kipper - Head of Therapeutic Drug Monitoring Unit at Epilepsy Society  
- Speaker 2: Dr Sara Zagaglia - Honorary Clinical Assistant and Clinical Research Fellow at University College London Hospitals NHS Foundation Trust. |
| 12:30pm - 2:00pm | Business meeting - TDM in Oncology Committee | Room B - Angelicum Congress Centre | Coordinators: Gareth Veal |
| 12:30pm - 2:00pm | Business meeting - Toxicology and Environmental Health Committee | Room C - Angelicum Congress Centre | Coordinators: Nicolas Venisse, David Kinniburgh |
| 2:45pm - 3:30pm | Plenary lecture 4: Clinical importance and pharmacological utility of using biomarkers in diagnosis of dementia. | Aula Magna - Angelicum Congress Centre | Plenary Speaker: Manuela Neuman |
| 3:30pm - 4:30pm | IATDMCt GENERAL ASSEMBLY | Aula Magna - Angelicum Congress Centre |  |
| 4:30pm - 4:45pm | Closing remarks | Aula Magna - Angelicum Congress Centre |  |